By Fineline Cube 
Nanjing Delova Biotech Co., Ltd. announced the completion of its Series C equity financing of approximately RMB 600 million (≈ US$83 million). The round was co-led by Govtor Capital, Efund Capital, Riverhead Capital, and Oriza Holdings.
Funding Details
| Item | Detail |
|---|---|
| Amount Raised | RMB 600 million (≈ US$83 million) |
| Round | Series C |
| Lead Investors | Govtor Capital, Efund Capital, Riverhead Capital, Oriza Holdings |
| Use of Proceeds | Clinical development of three late-stage pipeline candidates, indication expansion, IND filings for small-molecule pipelines |
| Company Focus | Non-addictive novel drugs in pain management |
Product Portfolio & Regulatory Milestones
Qamzova (Meloxicam)
- Status: Approved for marketing in China and United States
- Innovation: First 24-hour long-acting NSAID injection in China
- Regulatory Achievement: First Chinese novel analgesic drug to receive FDA marketing approval
- Special Recognition: Among very few domestic innovative drugs to receive FDA “Application Fee Waivers” support
QP-6211
- Status: NDA accepted by China’s NMPA in December 2025
- Innovation: World’s first long-acting ropivacaine injection with positive Phase III results from two clinical trials
- Mechanism: Next-generation amide local anesthetic with superior pain targeting and excellent cardiac/CNS safety
Company Profile
Founded in 2017, Delova Biotech specializes in developing non-addictive novel therapeutics for pain management—a critical focus area given global concerns about opioid dependency. The company has successfully transitioned from early-stage research to commercial-stage operations with multiple approved and near-term approvable products.
Strategic Outlook
The Series C funding positions Delova to:
- Accelerate late-stage clinical development across three pipeline candidates
- Expand indications for existing approved products
- Advance globally competitive small-molecule pipelines based on innovative targets through IND filings
- Strengthen global regulatory strategy leveraging existing FDA approval precedent
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and commercial expectations. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech